Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
What you need to know about flu treatments as cases spike across the US - 2In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 3Merz: 80% of Syrians in Germany should return in three years
- 42024 Manual for Light Extravagance Room Feel: What's Moving
- 5European Travel Objections for 2024
- The most effective method to Keep up with Proficient Handshakes in a Computerized World
- Illegal entries into Germany halve over two years, border police say
- Monetary Security: Building Serious areas of strength for an Establishment
- Moscow accuses Berlin of stifling the opposition
- Misremembering might actually be a sign your memory is working optimally
- Figure out How to Pick a Crematorium: Key Contemplations.
- 25 Most Beautiful Villages in France You Can Actually Visit
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- Here are 10 stores where you can get a free Thanksgiving turkey
